Our Blogs
Exploring the World of Unlisted Stocks
SBI Mutual Fund’s 3:1 bonus issue highlights strong financial performance, growing profitability, and long-term growth potential. This corporate action boosts investor confidence and strengthens the appeal of SBI Mutual Fund’s unlisted shares.
By Admin on 17 Dec, 2025
In-depth overview of Sterlite Grid 5 Limited as the demerged transmission infra arm of Sterlite Power, explaining its BOOM model, asset monetisation strategy, growth tailwinds, key risks and which investors should consider this unlisted infra bet.
By Admin on 08 Dec, 2025
PharmEasy, under new CEO Rahul Guha, is shifting from high cash burn to a profit-first model. With cost cuts, operational synergies, and focus on high-margin, recurring revenue, the company aims for EBITDA and PAT profitability by March FY27.
By Admin on 24 Nov, 2025
NCDEX has received board approval to launch a digital mutual-fund distribution platform, expanding beyond commodities. SEBI’s final clearance is pending. The move could boost competition, improve rural MF access, and reshape India’s distribution landscape.
By Admin on 17 Nov, 2025
Billionaire investor Radhakishan Damani has invested ₹90 crore in eyewear brand Lenskart ahead of its ₹8,000 crore IPO. With SEBI approval and strong financials, the IPO—expected in November 2025—could be a major event in India’s retail market.
By Admin on 27 Oct, 2025
A detailed data-driven review of Groww’s unlisted valuation, IPO prospects, profitability trends, and investor insights in October 2025—covering AUM growth, liquidity, and key risks.
By Admin on 13 Oct, 2025
PhysicsWallah records a remarkable 153% surge, reaching 4.46 million paid users in FY25. The growth highlights its hybrid learning model, strong engagement, cost control, and strategic expansion in India’s edtech space.
By Admin on 08 Oct, 2025
BVG India refiles IPO papers with SEBI after 4 years, increased offer size includes Rs 300 crore fresh issue
By Admin on 06 Oct, 2025
PharmEasy, one of Mumbai's leading health-tech unicorns, has taken a decisive financial step by raising ₹1,700 crore in a debt round. The capital will primarily be used to repay a costly Goldman Sachs loan, underscoring the company's efforts to balance between aggressive expansion and financial discipline. This development reflects both the challenges and strategic pivots shaping PharmEasy's journey in India's digital healthcare ecosystem.
By Admin on 19 Sep, 2025